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Background: In vivo models of uremia are important tools to study numerous aspects of acute and chronic kidney
disease. Mouse models are pivotal because most genetically engineered animal models are mice, which allow
dissecting the impact of selected target genes in renal failure. Adenine-based protocols to induce renal failure are
available in rats, but have not been adapted in mice due to their reluctance to consume adenine. In the current
paper we developed a novel method for induction of renal failure through dietary delivery of adenine mixed in a
casein-based diet.
Results: After an induction phase, a stable model of renal impairment was obtained (target urea range 80–100 mg/dL),
mimicking several aspects of chronic kidney disease - mineral and bone disorder including secondary
hyperparathyroidism, bone abnormalities and pathological elevation of FGF23. No deaths occurred and the level of
uremia was adaptable through adjustments of the adenine content, providing significant advantages compared to
existing models. In an 8-week proof-of-concept study, renal histology showed mainly a tubulointerstitial damage with
infiltrating leukocytes, interstitial edema and widening of the Bownman's space. Fibrosis was present in most animals as
defined by histology and gene expression changes of fibrosis markers. Parathyroid cell proliferation was markedly
increased but without signs of glandular hypertrophy. Skeletal histology showed increased trabecular bone and bone
marrow adiposity whereas bone biomarkers (CTX and PINP) suggested higher bone formation, but surprisingly, lower
bone resorption and perturbations in mineral metabolism.
Conclusions: We present a novel, non-surgical method for induction of renal failure in mice. This is an important
complement to existing uremic models for pathophysiological studies in acute and chronic kidney disease, especially in
terms of tubulointerstitial lesions.
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Chronic kidney disease (CKD) is a global health burden
[1], yet effective treatments for its prevention, progres-
sion and associated complications are currently lacking.
Animal models of renal failure are important tools to
study pathophysiological events in kidney disease that
allows translational studies aiming to improve manage-
ment of CKD patients. Due to the high availability of* Correspondence: tobias.larsson@ki.se
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reproduction in any medium, provided the orgenetically engineered mouse strains, uremic mouse
models provide the opportunity to investigate the impact
of specific target genes in the setting of renal failure.
Established techniques for induction of renal failure in
mice are mostly dependent on surgical interventions.
The most widespread methods currently used are unilat-
eral ureteral obstruction [2-7], which leads to interstitial
fibrosis by infiltration of macrophages and tubular cell
death by apoptosis and necrosis, and 5/6 nephrectomy
[8,9]. The latter technique usually involves two separate
procedures, first two thirds of one kidney is destructed
by electrocoagulation and after recovery a contra-lateral
nephrectomy is performed. The 5/6 nephrectomy model
has several limitations including a substantial mortality
rate when not performed adequately, non-reversibilityThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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procedure rather than impaired kidney function [10].
The method is also associated with relatively large inter-
individual and inter-laboratory variations and its avail-
ability may be compromised by lack of surgical expertise
and the appropriate operating facilities.
To circumvent these obstacles, we aimed at establishing
a novel, non-surgical model of renal failure in mice by
employing an adenine-based protocol. Importantly, there
are well-characterized protocols for adenine-induced renal
failure in rats, yet this technique has not been adapted in
mice due to their aversion to adenine feeding.
Methods
Animal experiments
The experiments were conducted in compliance with
the guidelines of animal experiments of Karolinska
Institutet and the study protocol was approved by the
regional ethical committee (Stockholm South ethical
committee, approval number S184-10 and appendix
S19-13). 8-week-old C57BL/6J mice were housed in
standard cages with wood chip bedding and a paper roll
for enrichment at constant ambient temperature (21–22°C)
and humidity (40-50%) with a 12-hour light cycle. All
animals had free access to tap water and the assigned diet.
Before study start, all mice were allowed acclimatization to
the animal facility conditions and the casein-based chow
during a 7-day period.
To provide an adenine-containing chow consumed by
the mice, adenine was mixed with a casein-based diet
that blunted the smell and taste. Adenine was purchased
from Sigma Aldrich (MO, USA) and the powdered
casein-based diet from Special Diets Services (SDS, UK)
(reference number 824522). Other ingredients of the diet
are maize starch (39.3%), casein (20.0%), maltodextrin
(14.0%), sucrose (9.2%), maize/corn oil (5%), cellulose
(5%), vitamin mix (1.0%), DL-methionine (0.3%) and
choline bitartrate (0.2%). Total phosphate content was
0.9% and total calcium content was 0.6%.
Data presented herein is derived from an 8-week
experiment using 8-week-old C57BL/6J wild-type mice.
To exclude the possibility of an impact of the casein diet
per see on renal function, the control group (n = 5) was
fed the same casein diet as the adenine group (n = 9) but
without addition of adenine.
Serum and urine biochemistries
Blood was collected after cardiac puncture at sacrifice and
by tail vein incision at intermediate time points. Urine was
collected as spot urine samples after spontaneous urin-
ation. Serum and urine calcium, phosphorous, creatinine
and urea levels were measured on a Konelab 20XTi
(Thermo Scientific, Finland). Creatinine concentrations
were validated with a colorimetric assay (BioChain, CA,USA) yielding nearly identical results (rho = 0.95 and 0.98
for serum and urine creatinine respectively) when com-
pared with the Konelab technique. PTH was measured by
a mouse intact PTH ELISA kit (Immutopics, CA, USA),
FGF23 with an intact FGF23 ELISA (Kainos, Japan) and
1,25(OH)2D, CTX and PINP with EIA kits (Immunodiag-
nostic Systems, UK).Histology
Kidneys and parathyroid glands were fixed in 4% formal-
dehyde, embedded in paraffin and sectioned according
to standard procedures. Bones were decalcified in a buf-
fer containing 20% formic acid. All tissues were subject
to Hematoxylin and Eosin staining. Kidney sections were
also stained for Periodic acid-Schiff stain (PAS) for poly-
saccharides and mucosubstances (VWR International,
Sweden), Trichrome (Ladewig) for muscle and collagen
(Histolab Products AB, Sweden) and von Kossa for min-
eralized tissue (VWR International), according to the
manufacturers instructions. The kidneys and bones were
evaluated in a blinded fashion by an experienced kidney
pathologist (AW) and bone pathologist (GA), respect-
ively. Immunohistochemistry was performed according
to standard protocols using a rabbit monoclonal anti-
Ki67 antibody (SP6 1:400, Thermo Scientific, CA, US)
and a rabbit anti-human Myeloperoxidase antibody
(A398 1:100, Dako, Denmark). Proliferation index in
parathyroid glands was calculated as the number of Ki67
positive cells divided by total number of cells in four
consecutive sections.Alizarin red and vascular calcification
The thoracic to abdominal part of the aorta (n ≥ 5 from
each group) was dissected, split longitudinally and laid flat.
The tissue was incubated with 1% alizarin red S-staining
solution (Alfa Aesar, Germany) at room temperature for
10 minutes and washed three times with 70% ethanol for
20 minutes each.Analysis of renal transcripts
Kidneys were homogenized using a TissueLyzer LT
(Qiagen, Netherlands) and total RNA was extracted
using E.Z.N.A. Total RNA Kit I (Omega Bio-tek, GA,
US). DNA was removed with E.Z.N.A. RNase-Free
DNase Set (Omega Bio-tek). First-strand cDNA was
synthesized using iScript cDNA Synthesis Kit (Bio-Rad,
Hercules, CA, US).
For real time qPCR analysis the CFX96 Real-Time
PCR Detection System and iQ SYBR Green Supermix
(Bio-Rad) were used. The relative gene expression was
calculated using the 2-ΔΔ Cq method normalizing the
gene of interest to β-actin in the same sample.
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GraphPad Prism 5.0 (GraphPad Software Inc, CA, US)
was used for statistical analysis. All values are expressed
as mean ± SEM unless otherwise stated. Differences be-
tween adenine-treated mice and controls were calculated
using the Mann–Whitney non-parametric test. P-values
<0.05 were considered statistically significant.
Results
Protocol development
We performed a series of pilot studies to establish the
optimal degree of renal impairment at which common
biochemical abnormalities associated with renal dys-
function occurred without increased morbidity or mor-
tality. For this purpose, serum urea levels ranging from
80–100 mg/dL were considered optimal. Urea levels
above 100 mg/dL were associated with increased mor-
bidity (weight loss and reduced physical activity),
whereas urea concentrations of <70-80 mg/dL led to a
weight gain and a partial reversal of biomarkers associ-
ated with impaired kidney function such as phosphor-
ous and PTH. Importantly, the casein-diet without
addition of adenine was used as control diet and did
not influence serum urea and creatinine levels or renal
histology compared to mice on a regular diet (data not
shown).
The required adenine dose to achieve the target urea
interval was determined to 0.3% adenine during a 10-day
“induction phase” and 0.15-0.20% during a “maintenance
phase”. When adhering to this urea range, no deaths oc-
curred during the entire study or in supporting pilot studies.
Accordingly, we propose that the adenine concentration can
be modified ad libitum between 0.15-0.20% during the
maintenance phase. Notably, we also evaluated adenine de-
livery by gavage, which resulted in an approximately 30%
overall mortality and higher variability in urea level and is
therefore not recommended.
Proof-of-concept study
We performed an 8-week experiment, a time frame gen-
erally endorsed in other uremic models of renal failure
to study CKD complications such as vascular calcifica-
tion [10]. The study protocol is shown in Figure 1. The
study was preceded by a 7-day adaptation phase of the
casein diet without addition of adenine, and comprised aInduction phaseAdaption phase
–7 10 0 15Day:
Adenine: 0% 0.3% 0.2% 0.15%
Baseline
Figure 1 Schematic view of the 8-week proof-of-concept study of ade
7-day adaptation phase, and comprised a 10-day induction phase (day 0–910-day induction phase (day 0–9) and a maintenance
phase (day 10–56). During the maintenance phase, the
adenine content was modified as described above in the
interval 0.15-0.20% to achieve the desired urea level of
80–100 mg/dL. Of note, lowering the adenine concen-
tration on day 15 and 40, from 0.2% to 0.15%, resulted
in a rapid decline in urea and PTH levels. However,
long-term reversibility and histological improvements
after adenine withdrawal was not examined.
Body weight and serum/urine biochemistries
The temporal changes in body weight and markers of
kidney function are depicted in Figure 2A. There was a
significant decline in body weight during the induction
phase but it was stabilized and essentially unaltered
during the maintenance phase. In accordance with pre-
vious reports urea appeared to be a more accurate
marker of uremia than creatinine, whereas the ratio of
creatinine/body weight paralleled the urea levels [11].
Decreased ratios between urine urea/serum urea and
urine creatinine/serum creatinine confirmed reduced
clearance of these metabolites (Figure 2A). Import-
antly, the adenine-exposed mice did not have increased
proteinuria compared to controls. This is likely
explained by the C57BL/6 strain's known resistance
towards development of proteinuria in combination
with the tubulointerstitial nature of the renal damage
in this model [12].
Markers of bone and mineral metabolism are shown
in Figure 2B. Similar to CKD patients, the adenine group
developed a significant hyperphosphatemia, secondary
hyperparathyroidism and severely elevated FGF23
paralleled by an increased urinary excretion of phos-
phorous [13]. There was no change in urinary excretion
of calcium (p = 0.66 for baseline versus endpoint). At
endpoint, CTX was significantly decreased whereas there
was a borderline significant increase in PINP in adenine-
treated mice compared to mice on a control diet,
suggesting a reduced bone resorption but an increased
bone formation (Figure 2B).
Histology
Histological analysis of kidneys, parathyroid glands and
bone are shown in Figure 3A-C and in Additional file 1:
Figure S1. Renal histology showed a peritubular leukocyteMaintenance phase
30 40 50 56
0.15%0.2 0% .2%
Endpoint
nine-induced renal failure in mice. The study was preceded by a



























































































































































































Figure 2 Body weight and biochemical parameters during the study. A: Body weight and renal function parameters during the study.
ΔBody weight (top): Body weight was reduced during the 10-day induction phase in the adenine-treated group but remained stable during the
maintenance phase until endpoint. Markers of kidney function: serum urea, serum creatinine/body weight, urine urea/serum urea and urine
creatinine/serum creatinine indicated reduced renal clearance rate in adenine-treated mice. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.
B: Temporal changes in serum biochemistries of mineral metabolism. At endpoint, there was a significant increase in serum inorganic
phosphorous, PTH and FGF23 but a decrease in 1,25(OH)2D level in adenine-treated mice. The bone marker CTX was decreased and PINP
borderline increased in the adenine group, supporting a reduced bone resorption but increased bone formation. *p < 0.05; **p < 0.01.
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that the kidney damage is mainly tubulointerstitial. Posi-
tive immunostaining for Myeloperoxidase confirmed that
the peritubular leukocytes were mainly comprised ofneutrophil granulocytes. (Additional file 2: Figure S2). An
increase in the Bowman´s space was seen in some but not
all glomeruli. Focal micro-abscesses were present in some,






















Figure 3 Histological analyses of kidneys, parathyroid glands
and bones. A: Renal histology showed deposition of symmetric
crystalline structures in a tubular lumen (arrow A), micro abscesses
(B) and dilated tubules (C). PAS staining showed dilated Bowman’s
space (D), atrophic tubuli with protein casts (“thyroidization”) (E) and
tubular atrophy with thickening of the tubular basement membrane
(F). Ladewig staining revealed a mild interstitial fibrosis (G). Extensive
calcification of tubular structures (H) was seen with von Kossa
staining. B: Parathyroid glands were not hypertrophic but had a
significantly increased proliferation rate determined by Ki67 index
(8.7 ± 0.7% vs 2.3 ± 0.5%; p < 0.0001). C: In bone, there was an
increased number and thickness of submetaphyseal bone trabeculae
(arrow A) and increased adipocyte content in the bone marrow (B).
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kidney is provided in Table 1.
Areal determination from serial sectioned parathyroid
glands revealed no overt glandular hypertrophy. Con-
versely, proliferation rate in the parathyroids determined
by Ki67 index was increased (Figure 3B), and in line
with the increased PTH level in adenine-treated mice.
Sections of femurs showed an extended bone trabeculae
and increased bone marrow adiposity consistent with
the serum pattern of the bone markers PINP and CTX.
Alizarin red stainings did not show any overt vascular
calcification in the thoracic aortas of adenine-exposed
mice (Additional file 3: Figure S3).
Gene expression changes of local inflammatory and
fibrosis markers
We analyzed the transcript levels of a number of locally
activated genes associated to renal inflammation and
fibrosis [14,15]. Inflammatory markers Mmp3 (Gene ID:
17392), Mmp9 (17395), Il7rα (16197), Ccl20 (20297) and
Ccl5 (20304) were all significantly upregulated in the
adenine-treated mice (Figure 4A), whereas Cxcr2 was
unchanged (data not shown). Corresponding markers of
fibrosis Tgfb1 (21803), Col1a1 (12842) and Ccl2 (20296)
were significantly upregulated in mice on an adenine
diet (Figure 4B). Primers used for real time qPCR
analysis are presented in Additional file 4: Table S1.
Discussion
Mouse models of uremia are important tools for in vivo
translational studies such as examining the impact of
specific genes in transgenic or knockout mice and to
validate potential therapeutic interventions prior to pre-
clinical testing in humans. The limitations of existing
surgical models of uremia in mice, including require-
ments of surgical skills, demand of animal facilities to
support post-operative care, high mortality rate and less
flexibility in terms of dynamic alterations in urea levels,
prompted us to develop a non-surgical model of renal
dysfunction based on dietary intake of adenine. This
approach has successfully been used in rats but not in
Table 1 Histopathological evaluation of kidneys from





(n = 5) (n = 8)
Glomeruli Sclerosis (present/absent) 0/5 0/8




structures in tubular lumina
(present/absent)
0/5 8/0
Cell debris/necrotic material and
PMN in tubular lumina (0–3)
0 (0–0) 1 (1–1)
Tubular atrophy (0–3) 0 (0–0) 2 (2–3)
Thyroidization (0–3) 0 (0–0) 1 (1–2)






Interstitium Fibrosis (0–3) 0 (0–0) 1 (1–1)
Inflammation (0–3) 0 (0–0) 0 (0–1)
Vessels Morphology (pathological/normal) 0/5 0/8
The parameters tubular atrophy, cell debris/necrotic material and
polymorphonuclear leukocytes (PMN) in tubular lumina, thyroidization,
interstitial fibrosis and interstitial inflammation are graded as follows: 0;
affecting 0-5% of the renal area, 1; 6-25%, 2; 26-50%, and 3; >50%. Data is
presented as median (range). Rounded cristalloid/amorphous structures in
tubular lumina, focal dilatation and focal calcium deposits in tubuli are graded
as present or absent. Vessel morphology is graded as pathological or normal.
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Accordingly, addition of adenine to a standard mouse
chow elicits high morbidity and mortality due to starva-
tion and malnutrition rather than renal failure. In our
model, this was circumvented by mixing the adenine in
a casein-based chow, in which the casein effectively



















Figure 4 Expression of renal-derived inflammatory and fibrosis genes
Marker of fibrosis Tgfb1, Col1a1 and Ccl2 were upregulated in adenine tre
White bars; control group, black bars; adenine group. ***p < 0.001.Since the sensitivity to adenine as well as food intake
may vary between various strains of mice, we propose a
protocol with ad libitum changes in adenine concentra-
tion between 0.15-0.20% during the maintenance phase.
The accepted variability in blood urea level during the
maintenance phase may cause inter-individual variations
in kidney function that could affect the phenotype. How-
ever such variability is inevitable and present in other
uremic animal models as well. On the contrary, provid-
ing a target urea interval provides the opportunity to
adjust blood urea levels according to the desired out-
come or mechanisms of interest.
The apparent improvement in kidney function after
lowering the adenine concentration, as indicated by a
decline in blood urea and PTH levels, suggests at least a
partial reversibility of renal impairment. However we did
not examine whether adenine discontinuation translated
into long-term histological improvements. Given the
severity of the renal histopathological lesions observed
after eight weeks of adenine exposure, we anticipate that
long-term adenine challenge will cause chronic renal
failure with less reversibility as observed in adenine-
induced uremia in rats [16]. Regardless, the possibility to
short-term modulate kidney function provides signifi-
cant benefits in terms of the possibility to extend study
protocols and to analyze outcome variables in various
strata of kidney function. Additional advantages of our
model include zero mortality, which limits the number
of animals needed for induction, and the small inter-
individual variation in renal function that contrasts the
5/6 nephrectomy model [10,17]. It also provides a good
option for researchers with limited surgical competence
and/or restrictions in post-operative care.
Some more common non-surgical options to study
uremia including radiation nephropathy and administra-




















. A) Inflammatory markers Mmp3, Mmp9, Il7rα, Ccl20 and Ccl5, and B)
ated mice. Relative gene expression in the control group is set to 1.
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tioned. However, these models are non-reversible,
strain-dependent and of limited use due to systemic tox-
icity. Genetic mouse models mimicking various aspects
of kidney failure are also available, but these are
compromised by the need for breeding to create com-
bined backgrounds with other genetically altered mouse
strains [20].
Several different uremic models have also been devel-
oped in rats. Advantages with rat models are that
collected blood and urine volumes are significantly
greater, blood samples at intermediate time points are
more easily obtainable and certain organs such as para-
thyroid glands are readily identified. Another apparent
difference is that rats tolerate higher adenine exposure,
which reportedly produce 3–5 times higher blood urea
concentrations than our model. This may also impact
renal histology since rats in additional to tubular damage
generally also suffer from extensive glomerular damage
which was not found in our model [21].
There are several biochemical findings of interest in
our model. Serum calcium level was unaltered in the
adenine-treated mice likely due to a compensatory rise
in PTH, which largely mimics the situation in patients
with CKD stage 3–4. Normal serum calcium concentra-
tions have also been reported in other CKD models [22].
Another striking finding is the continuous and marked
rise in FGF23 although other bone-mineral markers
remained more constant during the maintenance phase.
This supports the presence of renal derived factors that
regulates FGF23 synthesis in bone. Alternatively, the
tubular damage may severely hamper intact FGF23 deg-
radation leading to accumulation of circulating FGF23
protein. The pattern of bone markers suggesting an in-
creased bone formation but decreased bone resorption is
somewhat unexpected in a uremic model of secondary
hyperparathyroidism and anticipated high bone turnover
rate. The mechanism(s) underlying reduced bone resorp-
tion are unclear but could speculatively be due to im-
paired osteoclast function as a result of the exceptionally
elevated levels of FGF23.
Some potential limitations should be mentioned. We
cannot exclude the possibility of systemic toxicity or organ-
specific damages caused by the adenine. Because tubular
toxicity of adenine metabolites is the underlying mechan-
ism of adenine-induced renal failure [23,24], our model
primary reflects a tubulointerstitial disease whereas the
most common cause of CKD in human is glomerular scar-
ring secondary to vascular damage. Thus, our model should
not be regarded as a model of CKD per se but rather as a
complementary model of renal failure. We did not deter-
mine the dietary (caloric) intake, yet based on previous
experiments in rats the adenine-fed animals may have
somewhat lower overall dietary intake. Further, we did notperform dynamic bone histomorphometry although aden-
ine models in rats produce a high turnover phenotype.
Finally, possible strain differences as found in other mouse
models [25] warrant further investigation.
Conclusions
We present a novel non-surgical protocol for induction of
renal failure in mice. This will be an important comple-
ment to existing models for the study of pathophysiological
events and complications related to acute and chronic
kidney disease, specifically in terms of tubulointerstitial
lesions and abnormalities in mineral metabolism.
Additional files
Additional file 1: Figure S1. High resolution images of renal histology.
Hematoxylin and eosin stain (upper left panel) showed deposition of
symmetric crystalline structures in a tubular lumen, micro abscesses and
dilated tubules. PAS stain (upper right panel) showed dilated Bowman’s
space, atrophic tubuli with protein casts (“thyroidization”) and tubular
atrophy with thickening of the tubular basement membrane. Ladewig
stain (lower left panel) revealed a mild interstitial fibrosis. Extensive
calcification of tubular structures was seen with von Kossa stain (lower
right panel).
Additional file 2: Figure S2. Positive immunostaining for
Myeloperoxidase confirmed that the peritubular leukocytes were mainly
comprised of neutrophil granulocytes.
Additional file 3: Figure S3. Alizarin red S-staining of representative
segments from thoracic aorta. No vascular calcification was found in
control or adenine-treated mice.
Additional file 4: Table S1. List of primers used for real time qPCR
analysis.
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